Developer docs
API playgroundTry for free, no card

Search company profiles

TionLab Therapeutics

Full company profile

uuid00046cb

Namestring
TionLab Therapeutics
Legal namestring
TionLab Therapeutics Co., Ltd.
Websiteurl
tionlabrx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

TionLab Therapeutics is a South Korean pre-clinical-stage drug development company founded in 2021 that develops proprietary long-acting injectable drug delivery platforms. Its core technologies are the Depot Platform, which extends drug exposure duration from a single injection to enable monthly rather than weekly dosing (reducing injection frequency from 52 to 12 per year), and the Quject Sphere, a sister platform applied to obesity therapeutics. Additional formulation platforms target anti-diabetic and anti-obesity effects. The company operates from a research institute in Giheung-gu, Yongin-si and a head office in Gimhae-si, South Korea, with a small team of 1-10 employees under CEO Duck-soo Lim, and protects its technology through 10 patent applications across Korea, the US, Japan, Taiwan, and PCT.

The company's business model is platform licensing and co-development with pharmaceutical partners, generating revenue through licensing fees, development milestones, and potential royalties rather than direct product sales. Its lead program is a long-acting monthly semaglutide injectable developed jointly with Daewoong Pharmaceutical for the global obesity treatment market, for which IND was filed in April 2026 with clinical trials and commercial launch targeted within the year. Earlier commissioned research relationships with H Bio (biopharmaceutical eye drops), D-Bio (diabetes formulation), and D Pharmaceutical (clinical trial drug supply) demonstrate platform breadth across therapeutic areas including diabetes, obesity, cancer support, and ophthalmology.

TionLab's customer base is concentrated among Korean pharmaceutical partners, with Daewoong serving as both a strategic commercialization partner and an equity investor (KRW 1.25B participation in the 2024 KRW 5B round). The company has raised cumulative funding of approximately $3.75M USD from investors including E&Venture, IBK, AJU IB, Daewoong, Series Ventures, and Bluepoint Partners, supported by multiple Korean government programs (TIPS, KOTRA IKMP, First Penguin). It is not yet generating commercial revenue and remains in R&D and pre-clinical development.

Short descriptiontext

TionLab Therapeutics is a Korean pre-clinical biotech developing proprietary long-acting injectable drug delivery platforms (Depot and Quject Sphere) that reduce injection frequency, partnering with pharmaceutical companies like Daewoong to apply its technology to obesity, diabetes, and chronic disease treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGiheung, South Korea
HQ citystring
Giheung
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
long-acting injectables, drug delivery platforms, depot formulation technology, obesity therapeutics, pharmaceutical licensing
Industry1 code
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Delivery Technology
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing and Co-development
TypeLicensing Royalties
Description

The company licenses its proprietary drug delivery platform technology to pharmaceutical partners and enters co-development arrangements for joint development of long-acting injectable drugs. Revenue is generated through licensing fees, milestone payments tied to development progress, and potentially royalty arrangements upon commercialization.

tionlabrx.com
2Strategic Partnerships and Joint Ventures
TypeProfessional Services
Description

Revenue generated through strategic partnerships with pharmaceutical companies for joint development and commercialization of long-acting injectable treatments. Daewoong Pharmaceutical partnership represents a key commercial arrangement to develop and commercialize monthly semaglutide injectable for global obesity market.

tionlabrx.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TionLab Therapeutics is a drug development company that designs and licenses proprietary long-acting injectable drug delivery platforms — the Depot Platform and Quject Sphere — which convert existing injectable drugs into sustained-release monthly formulations. The company's lead program is a monthly semaglutide injectable for obesity co-developed with Daewoong Pharmaceutical, reducing dosing from 52 weekly injections per year to 12 monthly injections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduces injection frequency from 52 times per year to 12 times per year (77% reduction)
+1 more record
Product overview1 text field

TionLab Therapeutics is an R&D-focused company developing proprietary long-acting injectable drug delivery technologies. The core offering consists of the Depot Platform and Quject Sphere technology, which enable sustained drug release from a single injection. The company applies these platforms primarily to obesity and diabetes treatments, with its lead product being a long-acting monthly semaglutide injectable developed in partnership with Daewoong Pharmaceutical, reducing dosing frequency from weekly (52 times/year) to monthly (12 times/year) injections.

Product and service3 records
1Depot Platform
CategoryDrug Delivery Technology Platform
Description

Proprietary drug delivery platform that prolongs drug exposure from a single injection, enabling existing injectable drugs to be reformulated as long-acting monthly doses. Licensed to pharmaceutical partners for co-development across obesity, diabetes, and other chronic indications.

2Quject Sphere
CategoryDrug Delivery Technology Platform
Description

Proprietary drug delivery technology specifically designed for obesity treatment applications, enabling sustained-release long-acting injectable formulations. Made available to pharmaceutical partners (notably Daewoong Pharmaceutical) for co-development of obesity therapeutics.

3Long-acting Monthly Semaglutide Injectable
CategoryLong-acting Injectable Therapeutic
Description

Long-acting injectable formulation of semaglutide co-developed with Daewoong Pharmaceutical for the global obesity treatment market, reducing injection frequency from 52 weekly injections per year to 12 monthly injections per year.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-08
Description

Strategic partnership to jointly develop and commercialize a long-acting monthly semaglutide injectable for the global obesity treatment market. Combines TionLab's Quject Sphere drug delivery technology with Daewoong's CURE platform to reduce injection frequency from 52 to 12 times per year. Both companies filed for IND approval and plan to begin clinical trials with launch targeted within the year.

Strategic tierMinorTypeOthersAnnounced on2021-01-01
Description

Bluepoint Partners partnered with company for TIPS (Tech Incubator Program for startup) support and investment attraction facilitation.

3H Bio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

H Bio commissioned research on biopharmaceutical eye drops formulation conducted by company's research institute.

tionlabrx.com
4D-Bio
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Commissioned research on diabetes drug formulation conducted for D-Bio.

tionlabrx.com
5D Pharmaceutical
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Signed MOU with D Pharmaceutical to produce proprietary depot drug clinical trial drugs.

tionlabrx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Swedish specialty pharma company developing the FluidCrystal technology platform for long-acting injectable depots, commercialized products include Buvidal (weekly/monthly buprenorphine) and others. Directly comparable sustained-release injectable platform play serving chronic disease markets.

TypeDirect peer
Description

French clinical-stage biotech developing innovative formulations of insulin and other diabetes/obesity peptides (e.g., BioChaperone platform) for prandial and sustained-release delivery. Closely matches TionLab's anti-diabetic and anti-obesity platform focus with similar technology-licensing approach.

TypeDirect peer
Description

US biotech developing the ITCA 650 implantable osmotic pump that delivers exenatide continuously for 6-12 months for type 2 diabetes. Comparable mechanism of dramatically reducing dosing frequency for chronic metabolic disease via proprietary delivery technology.

TypeBroad incumbent
Description

Established specialty pharma with proprietary long-acting injectable technologies (ARISTADA, VIVITROL) for CNS disorders. Larger incumbent with overlapping long-acting depot technology, broader portfolio, and commercialization scale that TionLab aspires to reach.

TypeDirect peer
Description

US-based drug delivery platform company whose ENHANZE technology enables long-acting injectable formulations of partner drugs via recombinant human hyaluronidase. Closely comparable business model of licensing a proprietary delivery technology to large pharma partners for royalty revenue.

TypeEmerging player
Description

Clinical-stage biotech developing POZ-based polymer drug delivery technology for sustained-release CNS and other therapies. Earlier-stage but operates in the same long-acting injectable / sustained-release formulation space as TionLab's Depot platform.

TypeDirect peer
Description

US specialty pharma commercializing long-acting injectable products including EXPAREL (multivesicular liposome-based bupivacaine) and ZILRETTA for osteoarthritis. Comparable long-acting injectable focus with proprietary formulation technology and pharma licensing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TionLab Therapeutics

Drug Delivery Technologytionlabrx.com

TionLab Therapeutics is a Korean pre-clinical biotech developing proprietary long-acting injectable drug delivery platforms (Depot and Quject Sphere) that reduce injection frequency, partnering with pharmaceutical companies like Daewoong to apply its technology to obesity, diabetes, and chronic disease treatments.

What TionLab Therapeutics does

TionLab Therapeutics is a South Korean pre-clinical-stage drug development company founded in 2021 that develops proprietary long-acting injectable drug delivery platforms. Its core technologies are the Depot Platform, which extends drug exposure duration from a single injection to enable monthly rather than weekly dosing (reducing injection frequency from 52 to 12 per year), and the Quject Sphere, a sister platform applied to obesity therapeutics. Additional formulation platforms target anti-diabetic and anti-obesity effects. The company operates from a research institute in Giheung-gu, Yongin-si and a head office in Gimhae-si, South Korea, with a small team of 1-10 employees under CEO Duck-soo Lim, and protects its technology through 10 patent applications across Korea, the US, Japan, Taiwan, and PCT.

The company's business model is platform licensing and co-development with pharmaceutical partners, generating revenue through licensing fees, development milestones, and potential royalties rather than direct product sales. Its lead program is a long-acting monthly semaglutide injectable developed jointly with Daewoong Pharmaceutical for the global obesity treatment market, for which IND was filed in April 2026 with clinical trials and commercial launch targeted within the year. Earlier commissioned research relationships with H Bio (biopharmaceutical eye drops), D-Bio (diabetes formulation), and D Pharmaceutical (clinical trial drug supply) demonstrate platform breadth across therapeutic areas including diabetes, obesity, cancer support, and ophthalmology.

TionLab's customer base is concentrated among Korean pharmaceutical partners, with Daewoong serving as both a strategic commercialization partner and an equity investor (KRW 1.25B participation in the 2024 KRW 5B round). The company has raised cumulative funding of approximately $3.75M USD from investors including E&Venture, IBK, AJU IB, Daewoong, Series Ventures, and Bluepoint Partners, supported by multiple Korean government programs (TIPS, KOTRA IKMP, First Penguin). It is not yet generating commercial revenue and remains in R&D and pre-clinical development.

TionLab Therapeutics firmographics

Firmographics
Name
TionLab Therapeutics
Legal name
TionLab Therapeutics Co., Ltd.
Website
https://tionlabrx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
TionLab Therapeutics is a Korean pre-clinical biotech developing proprietary long-acting injectable drug delivery platforms (Depot and Quject Sphere) that reduce injection frequency, partnering with pharmaceutical companies like Daewoong to apply its technology to obesity, diabetes, and chronic disease treatments.
Ownership category
akta.pro rank

TionLab Therapeutics industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Long-acting injectables
  • Drug delivery platforms
  • Depot formulation technology
  • Obesity therapeutics
  • Pharmaceutical licensing

Where TionLab Therapeutics is headquartered

Location

Headquarters

HQ city
Giheung
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

TionLab Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing and Co-development: The company licenses its proprietary drug delivery platform technology to pharmaceutical partners and enters co-development arrangements for joint development of long-acting injectable drugs. Revenue is generated through licensing fees, milestone payments tied to development progress, and potentially royalty arrangements upon commercialization.
  2. Strategic Partnerships and Joint Ventures: Revenue generated through strategic partnerships with pharmaceutical companies for joint development and commercialization of long-acting injectable treatments. Daewoong Pharmaceutical partnership represents a key commercial arrangement to develop and commercialize monthly semaglutide injectable for global obesity market.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

TionLab Therapeutics product offering

Product offering

Core offering

TionLab Therapeutics is a drug development company that designs and licenses proprietary long-acting injectable drug delivery platforms — the Depot Platform and Quject Sphere — which convert existing injectable drugs into sustained-release monthly formulations. The company's lead program is a monthly semaglutide injectable for obesity co-developed with Daewoong Pharmaceutical, reducing dosing from 52 weekly injections per year to 12 monthly injections.

Product overview

TionLab Therapeutics is an R&D-focused company developing proprietary long-acting injectable drug delivery technologies. The core offering consists of the Depot Platform and Quject Sphere technology, which enable sustained drug release from a single injection. The company applies these platforms primarily to obesity and diabetes treatments, with its lead product being a long-acting monthly semaglutide injectable developed in partnership with Daewoong Pharmaceutical, reducing dosing frequency from weekly (52 times/year) to monthly (12 times/year) injections.

Differentiator

Problem solved

Functional benefit

Products and services

  • Depot Platform Proprietary drug delivery platform that prolongs drug exposure from a single injection, enabling existing injectable drugs to be reformulated as long-acting monthly doses. Licensed to pharmaceutical partners for co-development across obesity, diabetes, and other chronic indications.
  • Quject Sphere Proprietary drug delivery technology specifically designed for obesity treatment applications, enabling sustained-release long-acting injectable formulations. Made available to pharmaceutical partners (notably Daewoong Pharmaceutical) for co-development of obesity therapeutics.
  • Long-acting Monthly Semaglutide Injectable Long-acting injectable formulation of semaglutide co-developed with Daewoong Pharmaceutical for the global obesity treatment market, reducing injection frequency from 52 weekly injections per year to 12 monthly injections per year.

Quantifiable outcome

  • Reduces injection frequency from 52 times per year to 12 times per year (77% reduction)
  • +1 more outcomes

Companies that use TionLab Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

TionLab Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TionLab Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 8 May 2026Strategic partnership to jointly develop and commercialize a long-acting monthly semaglutide injectable for the global obesity treatment market. Combines TionLab's Quject Sphere drug delivery technology with Daewoong's CURE platform to reduce injection frequency from 52 to 12 times per year. Both companies filed for IND approval and plan to begin clinical trials with launch targeted within the year.
  • Bluepoint PartnersminorOthers · 1 January 2021Bluepoint Partners partnered with company for TIPS (Tech Incubator Program for startup) support and investment attraction facilitation.
  • H BiominorStrategic or Co-development Partner · 1 January 2021H Bio commissioned research on biopharmaceutical eye drops formulation conducted by company's research institute.
  • D-BiominorStrategic or Co-development Partner · 1 January 2021Commissioned research on diabetes drug formulation conducted for D-Bio.
  • D PharmaceuticalminorStrategic or Co-development Partner · 1 January 2021Signed MOU with D Pharmaceutical to produce proprietary depot drug clinical trial drugs.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

TionLab Therapeutics competitors and assessment

Company assessment

Direct peers

  • Camurus: Swedish specialty pharma company developing the FluidCrystal technology platform for long-acting injectable depots, commercialized products include Buvidal (weekly/monthly buprenorphine) and others. Directly comparable sustained-release injectable platform play serving chronic disease markets.
  • Adocia: French clinical-stage biotech developing innovative formulations of insulin and other diabetes/obesity peptides (e.g., BioChaperone platform) for prandial and sustained-release delivery. Closely matches TionLab's anti-diabetic and anti-obesity platform focus with similar technology-licensing approach.
  • Intarcia Therapeutics: US biotech developing the ITCA 650 implantable osmotic pump that delivers exenatide continuously for 6-12 months for type 2 diabetes. Comparable mechanism of dramatically reducing dosing frequency for chronic metabolic disease via proprietary delivery technology.
  • Halozyme Therapeutics: US-based drug delivery platform company whose ENHANZE technology enables long-acting injectable formulations of partner drugs via recombinant human hyaluronidase. Closely comparable business model of licensing a proprietary delivery technology to large pharma partners for royalty revenue.
  • Pacira BioSciences: US specialty pharma commercializing long-acting injectable products including EXPAREL (multivesicular liposome-based bupivacaine) and ZILRETTA for osteoarthritis. Comparable long-acting injectable focus with proprietary formulation technology and pharma licensing model.

Broad incumbents

  • Alkermes: Established specialty pharma with proprietary long-acting injectable technologies (ARISTADA, VIVITROL) for CNS disorders. Larger incumbent with overlapping long-acting depot technology, broader portfolio, and commercialization scale that TionLab aspires to reach.

Emerging players

  • Serina Therapeutics: Clinical-stage biotech developing POZ-based polymer drug delivery technology for sustained-release CNS and other therapies. Earlier-stage but operates in the same long-acting injectable / sustained-release formulation space as TionLab's Depot platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

TionLab Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TionLab Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

TionLab Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TionLab Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TionLab Therapeutics

What does TionLab Therapeutics do?

TionLab Therapeutics is a drug development company that designs and licenses proprietary long-acting injectable drug delivery platforms — the Depot Platform and Quject Sphere — which convert existing injectable drugs into sustained-release monthly formulations. The company's lead program is a monthly semaglutide injectable for obesity co-developed with Daewoong Pharmaceutical, reducing dosing from 52 weekly injections per year to 12 monthly injections.

Is TionLab Therapeutics a public or private company?

TionLab Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was TionLab Therapeutics founded?

TionLab Therapeutics was founded in 2021. It employs 1 to 10 people.

Where is TionLab Therapeutics based?

TionLab Therapeutics is headquartered in Giheung, South Korea, in the Asia region.

How does TionLab Therapeutics make money?

Two revenue lines are on record. Technology Licensing and Co-development is the primary driver. The others are strategic Partnerships and Joint Ventures.

Who are TionLab Therapeutics's main competitors?

Direct peers on record are Camurus, Adocia, Intarcia Therapeutics, Halozyme Therapeutics and Pacira BioSciences. Alkermes is listed as a broad incumbent. Serina Therapeutics is listed as an emerging player.

Does TionLab Therapeutics have an API?

No public API is recorded for TionLab Therapeutics.

What industry is TionLab Therapeutics in?

TionLab Therapeutics's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Korea HeraldBeyond Mounjaro: Korean drugmakers chase monthly obesity shotSamsung Epis Holdings, Daewoong, Dongkook Pharmaceutical, and Yuhan are racing to develop monthly obesity injections that would reduce dosing frequency from 52 weekly injections to just 12 annual shots, leveraging partnerships with local biotech firms like G2GBio, TionLab Therapeutics, and Inventage Lab. Daewoong has already submitted an investigational new drug application for its long-acting semaglutide-based treatment and aims to begin clinical trials by year-end, while Dongkook targets Phase 1 studies next year for its three formulations. Morgan Stanley Research projects the global obesity drug market could reach $150 billion by 2035, up from its previous forecast of $105 billion and last year's approximately $15 billion in sales.The Korea HeraldDaewoong Pharmaceutical, TionLab Therapeutics join hands to develop monthly obesity injectableDaewoong Pharmaceutical signed a strategic partnership agreement with TionLab Therapeutics to jointly develop and commercialize a long-acting monthly semaglutide injectable for the global obesity treatment market. The partnership combines TionLab's Quject Sphere drug delivery technology with Daewoong's CURE platform to reduce injection frequency from 52 to 12 times per year, aiming to improve patient convenience and long-term treatment adherence. Both companies filed for IND approval last April and plan to begin clinical trials with a launch targeted within the year.HankyungYoung Woo Lee, Director of Climate Tech Innovation at K-water, stated, “By 2025, the Startup Scale-Up Package will enable 203 companies to create 1,272 jobs"K-water (Korea Water Resources Corporation) reported that its 2025 Startup Scale-Up Package selected 203 companies, which collectively created 1,272 jobs, generated KRW 177.5 billion in revenue, and attracted KRW 68.2 billion in investment. The state-run water corporation, which manages the K-Testbed demonstration infrastructure across 75 public institutions and operates a KRW 525.4 billion Regional Innovation Venture Fund, received the 'Top Excellence' rating in the 2024 program evaluation and was selected as an exemplary startup support institution in Korea. A highlighted success story, Tionlab Therapeutics Co., Ltd., secured KRW 5 billion in investment from E&Venture, IBK, AJU IB, and Daewoong Pharmaceutical while advancing long-acting obesity treatment development through joint research with three domestic pharmaceutical companies.WebeconomyGimhae Biohealth and Industry Promotion Agency startup incubation company successfully attracts investment - Web EconomyGimhae Biohealth and Industrial Promotion Agency-backed startups Simply Care Bio and Tion Lab Therapeutics secured 300 million won and 200 million won in investments, respectively, from Series Ventures. The funding will support Simply Care Bio's development of health functional foods using omega-3 technology and enable Tion Lab Therapeutics to accelerate clinical trials for its drug delivery platform targeting diabetes and obesity. This investment highlights the success of local startup support programs in fostering regional biohealth innovation.PlatumSeries Ventures invests in Tion Lab Therapeutics, a next-generation drug delivery platform for new drug development.Series Ventures has invested in Tion Lab Therapeutics, a company specializing in next-generation drug delivery platforms. The funds will be directed toward animal evaluation costs for a long-acting injection designed to treat obesity by reducing weight by over 15% with monthly administration. This investment aims to secure clinical phase 1 approval and attract further funding.